14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $225.62 $260.34 Thursday, 2nd May 2024 UTHR stock ended at $258.13. This is 1.17% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 2.47% from a day low at $254.06 to a day high of $260.34.
90 days $208.62 $260.34
52 weeks $204.44 $261.48

Historical United Therapeutics Corporation prices

Date Open High Low Close Volume
Aug 21, 2023 $230.15 $231.57 $228.88 $231.14 204 857
Aug 18, 2023 $227.30 $230.35 $226.45 $229.80 270 300
Aug 17, 2023 $230.81 $234.75 $227.41 $228.12 1 170 442
Aug 16, 2023 $235.28 $236.66 $230.55 $230.77 245 177
Aug 15, 2023 $232.45 $236.76 $232.07 $235.73 180 598
Aug 14, 2023 $236.17 $237.27 $232.90 $233.26 212 426
Aug 11, 2023 $237.45 $239.72 $236.80 $237.80 260 618
Aug 10, 2023 $235.49 $238.32 $235.33 $237.15 197 640
Aug 09, 2023 $236.32 $240.27 $233.73 $235.01 198 317
Aug 08, 2023 $237.80 $240.53 $235.14 $236.78 301 808
Aug 07, 2023 $236.37 $239.12 $234.18 $237.80 308 576
Aug 04, 2023 $232.02 $238.93 $231.87 $236.37 436 132
Aug 03, 2023 $242.28 $243.78 $230.00 $231.87 655 766
Aug 02, 2023 $260.01 $261.48 $240.61 $240.85 941 550
Aug 01, 2023 $242.71 $243.16 $238.75 $240.13 246 845
Jul 31, 2023 $245.15 $245.15 $239.83 $242.72 305 078
Jul 28, 2023 $244.12 $246.69 $242.12 $245.17 250 718
Jul 27, 2023 $243.72 $243.72 $241.38 $242.77 193 921
Jul 26, 2023 $244.60 $244.60 $241.02 $242.84 281 276
Jul 25, 2023 $243.91 $246.33 $243.91 $244.60 287 618
Jul 24, 2023 $248.58 $250.43 $245.71 $245.73 349 143
Jul 21, 2023 $245.63 $249.06 $243.71 $248.24 233 282
Jul 20, 2023 $243.87 $246.77 $242.54 $244.34 303 606
Jul 19, 2023 $239.16 $242.46 $238.50 $242.19 206 479
Jul 18, 2023 $235.70 $238.49 $235.38 $237.91 240 948
Click to get the best stock tips daily for free!

About United Therapeutics Corporation

United Therapeutics United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a... UTHR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT